 ARCA biopharma, Inc. ABIO a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the closing of its previously announced registered direct offering with certain institutional and accredited investors of 348,000 shares of ARCAs common stock, at a purchase price of 9.00 per share, and pre-funded warrants to purchase 325,500 shares of common stock at a purchase price of 8.999 per warrant. The gross proceeds to ARCA, before deducting placement agent fees and other offering expenses, were approximately 6.1 million. The gross proceeds represent a mutually agreed reduction in the gross proceeds of the offering from the initial 9.4 million previously announced on June 1, 2020. 